Obicetrapib

NLS Pharmaceutics has filed a $75 million mixed securities shelf, signaling potential capital raising activities to support its clinical development pipeline in the near future.

NewAmsterdam Pharma reported positive Phase 3 results for obicetrapib, demonstrating significant LDL-C reduction and a favorable safety profile.

Rilzabrutinib demonstrated a 65% platelet response rate in ITP patients in the Phase 3 LUNA 3 trial, compared to 33% in the placebo group, supporting its potential as a first-in-class treatment.

Merck's sotatercept (Winrevair) met the primary endpoint in the Phase 3 ZENITH trial, demonstrating potential in treating pulmonary arterial hypertension.

New Amsterdam's Phase III TANDEM trial met its co-primary endpoints, demonstrating a significant reduction in LDL-C levels in patients with HeFH or ASCVD.